腭扁桃体非霍奇金淋巴瘤70例临床分析

 目的 探讨原发于腭扁桃体的非霍奇金淋巴瘤（NHL）的临床疗效及其预后因素。方法 回顾性分析1993年11月至1999年8月收治的70例原发于腭扁桃体的NHL的临床资料。根据Ann Arbor分期，Ⅰ期12例，Ⅱ期39例，Ⅲ期15例，Ⅳ期4例。根据1981年国际工作分类：低度恶性8例，中度恶性28例，高度恶性34例。单纯化疗组30例，单纯放疗组3例，综合治疗组37例。结果 全组总体生存率为56.3 ％，其中1、3、5年生存率分别为82.5 ％、67.3 ％、58.5 ％。高度恶性患者单纯化疗、单纯放疗、综合治疗的总体生存率分别为20.0 ％、0、52.6 ％（P＜0.05）。多因素分析证明，病理类型和近期疗效是影响预后的独立因素。结论 放化疗综合治疗可提高腭扁桃体NHL的疗效，病理类型和近期疗效是腭扁桃体NHL重要的预后因素

Clinical analysis of non-Hodgkin lymphoma of palatine tonsil-Report of 70 cases

Objective To investigate the treatment method and prognostic factors of patients with non-Hodgkin lymphoma(NHL) of palatine tonsil． Methods 70 patients with NHL of palatine tonsil were re－viewed． According to Ann Arbor staging classification，12 patients had stage Ⅰ, 39 stage Ⅱ, 15 stage Ⅲ and 4 stage Ⅳ. Working formulation was used in pathologic classification which was low grade 8 cases, intermedi－ate grade 28 cases and high grade 34 cases． 30 cases were treated by chemotherapy alone, 3 cases by radio－therapy alone, 37 cases by chemotherapy and radiotherapy． Results The overall survival rate was 56.3 ％． They were 82.5 ％ in 1 year, 67.3 ％ in 2 years and 58.5 ％ in 5 years, respectively． The overall survival rates in high grade cases of pathologic classification were 20.0 ％ in chemotherapy alone, 0 in radiotherapy alone, 52.6 ％ in chemotherapy and radiotherapy（P <0.05）, respectively． Multivariate analysis showed that the pathologic classification and tumor regressive condition were independent prognostic factors． Conclusion Combined modality therapy significantly improves the overall survival rate in non-Hodgkin lymphoma(NHL) of palatine tonsil． The pathologic classification and tumor regressive condition are the important prognostic fac－tors of patients with NHL of the tonsil．